Last update Aug. 23, 2021
Barbiturate with general properties similar to those of amobarbital. Hypnotic and sedative.
It is used to treat pain in preparations combined with paracetamol or caffeine.
Discontinued medication due to risk of overdose and abuse (Suddock 2020).
At the date of the last update, there was no available published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, low protein binding, prolonged half-life) make it probable that it will pass to milk in an amount that could be significant.
A 7-day-old newborn, whose mother was taking a butalbital (50 mg) -paracetamol-caffeine compound four times a day, presented sedation, lethargy, hypotonia, insufficient feeding and vomiting. The infant had butalbital levels in its urine(Vohra 2019).
Known safer alternatives are preferable during lactation, especially during the neonatal period and in the case of prematurity (Burch 2020 and 2019, Worthington 2013).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM